title: Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies.
abstract: The use of fetal hematopoietic stem cells for in utero transplantation to create permanent hematochimerism represents a new concept in fetal therapy. In one fetus with alpha-thalassemia, one with sickle cell anemia, and one with beta-thalassemia, we have transplanted fetal liver cells obtained from legal abortions in gestational weeks 6-11. The fetus with alpha-thalassemia was transplanted twice during pregnancy, in the 15th (20.4 x 10(8) cells/kg) and in the 31st weeks of gestation (1.2 x 10(8) cells/kg), and is now two years of age. One fetus with sickle cell anemia received its transplant in the 13th week of gestation (16.7 x 10(8) cells/kg), and is now one year old. The fetus with beta-thalassemia was transplanted in 18th week (8.6 x 10(8) cells/kg), and is now three months old. Engraftment was evaluated by chromosomal analysis (sex chromosomes), red cell phenotyping, HLA class I and II typing, and PCR (polymerase chain reaction) for Y chromosome-specific sequences and DNA polymorphisms in cord and peripheral blood. The children with alpha- and beta-thalassemia underwent bone marrow aspirations at 3 and 7 months of age, respectively. In neither of these cases were we able to detect convincing evidence of stem cell engraftment. Thus, the administration of fetal stem cells to fetal recipients after the 12th week of gestation did not result in permanent hematochimerism. It remains to be determined whether the engraftment process can be promoted by earlier transplantations and/or higher cell doses.
authors.affiliation: Department of Obstetrics and Gynaecology, Huddinge Hospital, Stockholm, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Westgren
authors.forename: O
authors.initials: O
authors.lastname: Ringden
authors.forename: S
authors.initials: S
authors.lastname: Eik-Nes
authors.forename: S
authors.initials: S
authors.lastname: Ek
authors.forename: M
authors.initials: M
authors.lastname: Anvret
authors.forename: A M
authors.initials: AM
authors.lastname: Brubakk
authors.forename: T H
authors.initials: TH
authors.lastname: Bui
authors.forename: A
authors.initials: A
authors.lastname: Giambona
authors.forename: T
authors.initials: T
authors.lastname: Kiserud
authors.forename: A
authors.initials: A
authors.lastname: Kjaeldgaard
authors.forename: A
authors.initials: A
authors.lastname: Maggio
authors.forename: L
authors.initials: L
authors.lastname: Markling
authors.forename: A
authors.initials: A
authors.lastname: Seiger
authors.forename: F
authors.initials: F
authors.lastname: Orlandi
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000628:therapy*; D005260:Female; D016332:Fetal Tissue Transplantation; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D011247:Pregnancy; D011295:Prenatal Care; D017085:alpha-Thalassemia / Q000628:therapy*; D017086:beta-Thalassemia / Q000628:therapy*